Aireen is a CE MDR IIb certified medical device that utilizes AI to autonomously analyze digital images of the retina for the early detection of chronic diseases. This non-invasive technology provides diagnostic results within 60 seconds, improving screening compliance and reducing late-stage diagnoses while enhancing access to timely medical care.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of chronic retinal diseases often relies on specialized equipment and trained personnel, leading to delays in diagnosis and limited access to care, particularly in underserved areas. This can result in delayed treatment and increased risk of vision loss.
Solution
Aireen offers an autonomous AI-powered medical device that analyzes digital images of the retina to detect chronic diseases in under 60 seconds. The device is CE MDR IIb certified, indicating its compliance with European medical device regulations for safety and performance. By automating the analysis process, Aireen aims to improve screening compliance, reduce late-stage diagnoses, and enhance access to timely medical care. The system is designed for ease of use by any healthcare personnel, enabling large-scale screening programs and extending expert capacity.
Target Audience
The primary target audience includes healthcare providers seeking to improve screening efficiency, payers aiming to reduce costs associated with late-stage diagnoses, and patients who need improved access to early disease detection.
Features
- AI-driven autonomous analysis of retinal images
- Diagnostic results available within 60 seconds
- Cloud-based service with a pay-as-you-go model
- Non-invasive and convenient examination process
- CE MDR IIb certification